Globus Medical (NYSE:GMED) Stock Gets Price Target Boost from Wells Fargo & Company

Globus Medical (NYSE:GMED) had its price target lifted by Wells Fargo & Company from $99.00 to $100.00 in a research note issued on Friday, Benzinga reports. The firm presently has an “overweight” rating on the medical device company’s stock. Wells Fargo & Company‘s price objective would suggest a potential upside of 41.51% from the company’s previous close.

Several other brokerages have also issued reports on GMED. UBS Group began coverage on shares of Globus Medical in a research report on Tuesday, July 28th. They issued a “neutral” rating and a $82.00 target price for the company. Truist Financial reduced their target price on Globus Medical from $115.00 to $100.00 and set a “buy” rating on the stock in a research note on Thursday, July 16th. Weiss Ratings restated a “hold (c+)” rating on shares of Globus Medical in a research report on Friday, October 9th. Royal Bank Of Canada dropped their price target on Globus Medical from $115.00 to $85.00 and set an “outperform” rating for the company in a research note on Thursday, October 1st. Finally, Zacks Research raised Globus Medical from a “hold” rating to a “strong-buy” rating in a research note on Monday, August 10th. Two investment analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and six have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $96.92.

Globus Medical Price Performance

GMED stock opened at $70.67 on Friday. Globus Medical has a one year low of $70.39 and a one year high of $101.40. The stock has a market cap of $9.49 billion, a PE ratio of 17.36, a P/E/G ratio of 1.14 and a beta of 0.98. The firm has a 50 day simple moving average of $77.20 and a two-hundred day simple moving average of $83.18.

Globus Medical (NYSE:GMED) last issued its quarterly earnings results on Thursday, November 5th. The medical device company reported $1.23 EPS for the quarter, topping analysts’ consensus estimates of $1.20 by $0.03. The firm had revenue of $763.72 million for the quarter, compared to analyst estimates of $792.39 million. Globus Medical had a net margin of 17.76% and a return on equity of 14.51%. The business’s revenue for the quarter was down .7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.18 EPS. Globus Medical has set its FY 2026 guidance at 4.950-5.050 EPS. On average, research analysts expect that Globus Medical will post 4.99 EPS for the current fiscal year.

Insider Buying and Selling at Globus Medical

In other Globus Medical news, Director James R. Tobin sold 30,000 shares of Globus Medical stock in a transaction that occurred on Tuesday, September 15th. The shares were sold at an average price of $74.58, for a total transaction of $2,237,400.00. Following the transaction, the director directly owned 15,000 shares of the company’s stock, valued at approximately $1,118,700. This trade represents a 66.67% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Stephen Zarrilli sold 25,000 shares of Globus Medical stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $87.04, for a total transaction of $2,176,000.00. Following the transaction, the director directly owned 25,000 shares in the company, valued at $2,176,000. This trade represents a 50.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 60,000 shares of company stock worth $4,838,400 over the last ninety days. Insiders own 18.38% of the company’s stock.

Hedge Funds Weigh In On Globus Medical

Several institutional investors and hedge funds have recently made changes to their positions in GMED. Elevation Wealth Partners LLC raised its position in Globus Medical by 2,178.6% in the 2nd quarter. Elevation Wealth Partners LLC now owns 319 shares of the medical device company’s stock worth $25,000 after purchasing an additional 305 shares during the period. Continuum Advisory LLC bought a new stake in Globus Medical in the second quarter worth $25,000. Root Financial Partners LLC purchased a new stake in Globus Medical during the third quarter valued at about $29,000. Heritage Family Offices LLP purchased a new stake in Globus Medical during the third quarter valued at about $31,000. Finally, Jacobi Capital Management LLC purchased a new stake in Globus Medical during the third quarter valued at about $40,000. Institutional investors own 95.16% of the company’s stock.

Trending Headlines about Globus Medical

Here are the key news stories impacting Globus Medical this week:

• Positive Sentiment: Third-quarter adjusted earnings were $1.23 per share, ahead of the $1.20 consensus and up from $1.18 a year earlier. Globus also increased its share-repurchase authorization by $500 million, offering potential support for shareholder returns. Third-quarter results and repurchase announcement
• Neutral Sentiment: Analyst views were mixed: Canaccord and Needham cut their price targets but maintained Buy ratings, while Wells Fargo slightly raised its target and kept an Overweight rating. The company is also seeking acquisitions, though the provided report does not detail potential deals. Report on acquisition plans
• Negative Sentiment: Revenue of $763.7 million missed the $792.4 million analyst estimate and declined 0.7% year over year. Full-year 2026 revenue guidance of $3.1 billion is below the roughly $3.2 billion consensus; management cited spine-product launch delays and weak Nevro sales, weighing on expectations despite EPS guidance being broadly in line. Q3 call highlights and outlook
• Negative Sentiment: BMO Capital Markets downgraded GMED from Outperform to Market Perform and cut its price target, adding to concerns about the outlook. Coverage of the stock decline

About Globus Medical